Edgewise Therapeutics :
EWTX
EWTX
Stock Data
$23.71
$0.39 (1.67%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Edgewise Therapeutics is a biopharmaceutical firm focused on creating treatments for muscle disorders. Its flagship product, EDG-5506, is an oral medication currently in Phase II trials, aimed at treating dystrophinopathies such as Duchenne and Becker muscular dystrophy. The company is also working on EDG-7500 for severe cardiac disorders, now in Phase I trials. Additionally, Edgewise is developing a range of precision medicine candidates targeting specific muscle proteins to combat genetically defined muscle conditions. Founded in 2017, the company is based in Boulder, Colorado.
